Ageing
Conditions
Brief summary
The purpose of this clinical trial is to understand whether oral vitamin C can help delay the aging of middle-aged and elderly individuals, search for sensitive biomarkers of human aging, and provide new paradigms and scientific guidance for aging intervention with small molecule drugs. The main questions it aims to answer are as follows: * Can oral vitamin C effectively improve the aging-related indicators? * What is the safety of participants when taking vitamin C supplements? Researchers will compare vitamin C with a placebo to observe whether vitamin C is effective in intervening in the aging of middle-aged and elderly individuals. Participants need to: * Take 2 tablets (250mg/tablet) of vitamin C or placebo after breakfast and dinner every day for 12 consecutive months; * Go to the designated place for a face-to-face follow-up every 6 months and receive a telephone follow-up every 2 months, and pick up subsequent drugs during the follow-up; * Honestly inform the medication situation during each follow-up; * Report any discomfort or adverse reactions that occur during the treatment process to the researchers; * Fill in a questionnaire about their own health status during each follow-up; * After 6 months and 12 months of intervention, conduct a comprehensive health examination as required, including blood tests and other items.
Interventions
DIETARY_SUPPLEMENTVitamin C
Participants swallow synthetic vitamin C tablets 500mg with water, twice a day.
OTHERPlacebo
Participants swallow tablets with the same texture, flavor, and appearance as the experimental group 500mg with water, twice a day.
Sponsors
The First Affiliated Hospital of Nanchang University
People's Hospital of Quzhou
Peking University Third Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* Age: 55-65 years (for the experimental and control groups) or 18-70 years (for the baseline control group assessing aging changes). * Health Status: Deemed to be in good health based on medical evaluation, including medical history, physical examination, laboratory tests, and cardiac monitoring. * Weight: BMI within the range of 18.5-28 kg/m². * Informed Consent: Capable of signing the informed consent form and complying with the requirements and restrictions outlined in the study protocol.
Exclusion criteria
* Disease Status:Uncontrolled medical conditions or any disease that, in the investigator's opinion, may pose an inappropriate risk or contraindication or interfere with the study's objectives, conduct, or evaluation.Severe chronic or acute diseases (e.g., cancer, heart failure, renal insufficiency, COPD, diabetes, active liver disease, metabolic acidosis, poorly controlled hypertension, epilepsy, recent cardiovascular events, inflammatory bowel disease, neurological disorders, infectious diseases, severe autoimmune diseases, etc.). * Weight: BMI \< 18.5 or BMI \> 28. * Substance/Alcohol Abuse: Ongoing alcohol or drug abuse, or excessive alcohol consumption. * Medical History: History of gastrointestinal diseases, hyperuricemia, kidney or urinary tract stones, glucose-6-phosphate dehydrogenase deficiency, or paroxysmal nocturnal hemoglobinuria. * Allergy: Allergy to vitamin C or any component of its formulation. * Recent Medication Use: Use of high-dose vitamin C, vitamin E, low-dose aspirin, acarbose, metformin, NMN/NR, or other anti-aging/weight-loss drugs within the past 3 months. * Informed Consent: Inability to provide informed consent. * Other: Any physical condition that, in the investigator's opinion, may adversely affect the study process or outcomes. * Clinical Research Participation: Participation in any other clinical research within 3 months prior to screening or during the study period, or receipt of chemotherapy, radiotherapy, biologic therapy, small-molecule therapeutic agents, or investigational drugs, with incomplete recovery from related side effects (excluding alopecia or potential neuropathy).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluate the effectiveness of vitamin C in intervening in aging | 12 months | DNA methylation composite clock |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| proteomics | 12 months | proteomics in blood |
| metabolomics | 12 months | metabolomics in blood |
| gut microbiome | 12 months | gut microbiome in fecal sample |
| Cognitive function | 1 year | Trail Making Test |
| Physical Fitness Test | 1 year | The score of Purdue pegboard test, Grip Strength Test，and Single Leg Stand Test with Eyes Closed |
| blood cell transcriptomics | 12 months | blood cell transcriptomics |
| Motor Function | 1 year | Hamilton Anxiety Scale |
| muscle mass | 1 year | By means of measurement of lean body mass using dual-energy X-ray absorptiometry (DXA) |
| Cardiovascular disease | 1 year | Standardised composite score (Z score) of systolic blood pressure, LDL cholesterol, and body-mass index (BMI). |
| Vitamin C level | 1 year | Vitamin C level in serum |
| Maximal oxygen consumption | 1 year | Maximal oxygen consumption |
Countries
China
Contacts
Primary ContactTian Tian
Outcome results
None listed